SCHEMBL4860057

SCHEMBL4860057

COc1cc(OC)c(NC(=O)c2ccc(Cc3cc([Si](C)(C)C)ccc3C)o2)c(OC)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GNRHR P30968 2/20 0.66
FPR1 P21462 1/20 0.66
GPR183 P32249 1/20 0.66
GPR119 Q8TDV5 1/20 0.66
ALDH1A1 P00352 3/20 0.46
LMNA P02545 2/20 0.46
HPGD P15428 2/20 0.46
TP53 P04637 1/20 0.46
MAPT P10636 5/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
S1PR4 O95977 3/20 0.43
POLB P06746 4/20 0.43
S1PR5 Q9H228 1/20 0.42
S1PR2 O95136 1/20 0.40
KDM4E B2RXH2 2/20 0.40
GAA P10253 1/20 0.40
MAPK1 P28482 2/20 0.39
KMT2A Q03164 3/20 0.39
CYP1A2 P05177 3/20 0.39
CYP3A4 P08684 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4864364 0.91 GNRHR (0.55) GNRHRFPR1GPR183GPR119ALDH1A1
SCHEMBL14395921 0.85 GNRHR (0.65) GNRHRFPR1GPR183GPR119ALDH1A1
SCHEMBL4852219 0.83 GNRHR (0.59) GNRHRFPR1GPR183GPR119ALDH1A1
SCHEMBL4860579 0.83 GNRHR (0.54) GNRHRFPR1GPR183GPR119ALDH1A1
SCHEMBL5835400 0.82 GNRHR (0.69) GNRHRFPR1GPR183GPR119ALDH1A1
SCHEMBL5835519 0.81 GNRHR (0.63) GNRHRFPR1GPR183GPR119ALDH1A1
SCHEMBL5834928 0.80 GNRHR (0.67) GNRHRFPR1GPR183GPR119ALDH1A1
SCHEMBL31060713 0.80 GNRHR (1.00) GNRHRFPR1GPR183GPR119
SCHEMBL5705276 0.80 GNRHR (0.71) GNRHRFPR1GPR183GPR119ALDH1A1
SCHEMBL208907 0.80 GNRHR (1.00) GNRHRFPR1GPR183GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7407649-B2 Compounds having a benzene ring substituted with 1 or 2 trialkylsilyl(alkyl) groups and at least 2 additional aryl or heteroaryl rings: 5-[2-methyl-5-(trimethylsilyl)phenoxy]-N-(2,6-dimethoxyphenyl)furan-2-carboxamide; Gonadotropin-Releasing Hormone antagonists; anticancer agents PARADIGM THERAPEUTICS LTD (GB) 2008-08-05 US claimed
EP-1644385-B1 SILICON COMPOUNDS AND THEIR USE TAKEDA CAMBRIDGE LTD (GB) 2007-08-29 EP claimed
US-20070110708-A1 Silicon compounds and their use PARADIGM THERAPEUTICS LTD (GB) 2007-05-17 US claimed
US-7407649-B2 Compounds having a benzene ring substituted with 1 or 2 trialkylsilyl(alkyl) groups and at least 2 additional aryl or heteroaryl rings: 5-[2-methyl-5-(trimethylsilyl)phenoxy]-N-(2,6-dimethoxyphenyl)furan-2-carboxamide; Gonadotropin-Releasing Hormone antagonists; anticancer agents PARADIGM THERAPEUTICS LTD (GB) 2008-08-05 US disclosed
EP-1644385-B1 SILICON COMPOUNDS AND THEIR USE TAKEDA CAMBRIDGE LTD (GB) 2007-08-29 EP disclosed
US-20070110708-A1 Silicon compounds and their use PARADIGM THERAPEUTICS LTD (GB) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070110708-A1 Silicon compounds and their use SOST, SMAD3, SMAD2 GNRHR 1621/4885FPR1 3685/4885GPR183 4141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.